MiniMed, MRG (Medical Research Group) depress Medtronic's profits:
This article was originally published in Clinica
Executive Summary
Profit figures returned by Medtronic for the second quarter of fiscal 2002 were expectedly low, US analysts reported last week. Against net earnings of $309 million last year, the Minneapolis company reported a figure of $66.7 million for the current year's second quarter. This reflected the early year purchase of MiniMed and Medical Research Group (see Clinica No 960, p 1) for some $3.7 billion. These buys will continue to enhance reported revenue more than earnings per share, said Medtronic's CFO, Bob Ryan. Organic growth rates were good for the quarter, said the analysts. Sales were up 17% at $1.57 billion.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.